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Abstract
P-glycoprotein, a human multidrug resistance transporter, has been extensively studied due to its importance to human
health and disease. In order to understand transport kinetics via P-gp, confluent cell monolayers overexpressing P-gp are
widely used. The purpose of this study is to obtain the mass action elementary rate constants for P-gp’s transport and to
functionally characterize members of P-gp’s network, i.e., other transporters that transport P-gp substrates in hMDR1-
MDCKII confluent cell monolayers and are essential to the net substrate flux. Transport of a range of concentrations of
amprenavir, loperamide, quinidine and digoxin across the confluent monolayer of cells was measured in both directions,
apical to basolateral and basolateral to apical. We developed a global optimization algorithm using the Particle Swarm
method that can simultaneously fit all datasets to yield accurate and exhaustive fits of these elementary rate constants. The
statistical sensitivity of the fitted values was determined by using 24 identical replicate fits, yielding simple averages and
standard deviations for all of the kinetic parameters, including the efflux active P-gp surface density. Digoxin required
additional basolateral and apical transporters, while loperamide required just a basolateral tranporter. The data were better
fit by assuming bidirectional transporters, rather than active importers, suggesting that they are not MRP or active OATP
transporters. The P-gp efflux rate constants for quinidine and digoxin were about 3-fold smaller than reported ATP
hydrolysis rate constants from P-gp proteoliposomes. This suggests a roughly 3:1 stoichiometry between ATP hydrolysis and
P-gp transport for these two drugs. The fitted values of the elementary rate constants for these P-gp substrates support the
hypotheses that the selective pressures on P-gp are to maintain a broad substrate range and to keep xenobiotics out of the
cytosol, but not out of the apical membrane.
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Introduction
P-glycoprotein (P-gp) is a member of the ATP binding cassette
(ABC) family of proteins that has been extensively studied because
of its ability to render cells resistant to many chemotherapeutic
agents and for causing clinically important drug-drug interactions
[1],[2],[3],[4].AmolecularunderstandingofP-gpactivityrequires
both structural knowledge [5], [6], [7], [8] and functional
knowledge of transport kinetics in physiologically relevant systems
[9], [10], [11], [12], [13], [14]. Confluent cell monolayers are
widely used as models for human tissues in which P-gp is expressed
[14], [15], [16], [17], [18], [19]. Here, we use a confluent
monolayer of hMDR1-MDCKII cells to develop a functional
description of the P-gp associated multi-transporter network by
obtaining elementary rate constants that regulate the flow of several
P-gp substrates between apical and basolateral compartments.
Figure 1 shows the basic transport pathways across a confluent
cell monolayer. There is partitioning of substrates into the
membranes they face; passive permeability across the lipid
bilayers; facilitated transport across both the basolateral and
apical membranes; and both primary and secondary active
transport. P-gp’s primary active transport across the apical
membrane is modeled using Eq (1), the standard Michaelis-
Menten reaction
T0zCPC /   ? {
k1
kr
{ TC  ?
k2 { T0zCA ð1Þ
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substrate in the inner apical membrane, T1 is the transporter
bound to substrate, and CA is the substrate after efflux into the
apical compartment. P-gp’s ATPase activity is not measured
within a confluent cell monolayer, but is required for efflux from
P-gp into the apical compartment [20], [21], [22]. However, we
have shown that P-gp efflux rates are the same at the beginning of
an experiment and 3 hr later, so the required ATP levels are being
maintained throughout the 4–6 hr experiment [23].
Typically, the kinetic analysis of transcellular transport uses some
form of Michaelis-Menten steady state equations [2], [10], [12],
[14], [16], [24], [25], [26]. While these equations can often fit the
efflux data for confluent cell monolayers, the fitted Vmax and KM
parameters are complex convolutions of the elementary rate
constants. We showed this using simulated transport kinetics from
our mass action model for the confluent cell monolayer. We
analyzed the model data using Michaelis-Menten steady state
equations [27]. The basic conclusion was that the value of the fitted
Michaelis constant KM to the simulated data was not correlated with
the standard value of KM=(k2+kr)/k1, from the elementary rate
constants used to create the simulations in the first place. Thus, two
experimentally fitted KM values that are close to one another
numerically could come from original (k2+kr)/k1 values that differ by
as much as 3 orders of magnitude. This is the consequence of the
convolution of all the kinetic parameters that drive P-gp transport
into just a single ‘‘KM’’, which has a small probability of predicting
the in vivo situation. We believe that the elementary rate constants
will extrapolate in vivo much more successfully.
The need to know the elementary rate constants extends to the
basic IC50 analysis of transport. For the confluent cell monolayer,
when the dissociation constant of the inhibitor to P-gp is denoted
KI, we have shown that the ratio of the IC50/KI increases with
increased P-gp surface density and probe-substrate elementary
efflux rate constants and decreases with the contributions of other
probe-substrate transporters [28]. The simple IC50 analysis is very
different with confluent cell monolayers, or tissue, than it is with
water soluble enzymes, upon which the standard IC50 equation
were tested [28].
Obviously, obtaining these elementary rate constants is a
difficult fitting problem requiring robust numerical approaches.
Our previous fittings were accomplished using a hierarchical
approach, with several fitting steps being manual [23], [29], [30].
It’s limitations were that it could analyze only one drug
concentration at a time per computer processor, the collation of
the consensus rate constants had to be done manually, yielding
broad ranges of ‘‘equivalent best fits’’ which changed as new
datasets were examined and, worse, about a third of the datasets
failed to yield convergent answers with the algorithm for no
apparent reasons. These were serious limitations.
To overcome these problems, we have developed two major
computational refinements: 1) a new fitting program that
determines the elementary rate constants simultaneously from all
relevant data sets, which can run serially or in parallel; and 2) the
use of a global optimization package based upon the Particle
Swarm algorithm [31], which proved to be far faster and more
accurate. The combination of these two refinements provides
robustness, i.e. all the applicable data can be fitted simultaneously.
A comparison of the two fitting algorithms showed that the
average coefficient of variation per fitted data set, ,CV/dataset.
is about 35% smaller using the Particle Swarm algorithm and fits
were completed about 20-fold faster.
The fitting of all data has led to significant changes from
previous estimates for kinetic parameters and P-gp efflux active
surface density. The fitted values of the kinetic parameters still
make sense with respect to the hypothesis that the primary
selective pressure on P-gp to respond to all of xenobiotics, many of
which it is encountering for the first time. The older algorithm
supported the same hypothesis [23].
Materials and Methods
Experimental
P-gp substrates, inhibitors, cell line and culture conditions have
previously been described [23], [29], [30]. Briefly, Madin-Darby
Canine Kidney cell line overexpressing human MDR1 (MDCKII-
hMDR1) was purchased from the Netherlands Cancer Institute
(NKI, Amsterdam, Netherlands). Cells were split twice a week and
maintained in culture media (DMEM supplemented with 10%
Fetal Bovine Serum, 50 units/ml penicillin and 50 mg/ml
streptomycin). Cells were kept at 37uCi n5 %C O 2.
P-gp mediated transport was measured in 12-well transwell
Costar plates fitted with polycarbonate membrane inserts. Cells
were seeded at a density of 175,000–200,000 cells per insert and
grown for four days in culture media. Cells were given fresh media
one day after seeding. Prior to the experiment, culture media was
removed and cells were preincubated for 30 minutes with either
transport medium alone (see above) or transport medium
supplemented with 2 mM GF120918 to inhibit P-gp. Transport
of a range of concentrations of amprenavir, loperamide, quinidine
and digoxin across the confluent monolayer of cells was measured
in both directions, i.e. apical to basolateral (A.B) and basolateral
to apical (B.A) in the presence and absence of GF120918. For
incubations in the presence of GF120918, the inhibitor was added
to both chambers. 0.5 mCi/ml of
3H-amprenavir,
3H-quinidine,
3H-loperamide, or
3H-digoxin was added to each respective drug
concentration to allow quantitation of transport from donor to
receiver chambers by liquid scintillation counting. In addition,
0.25 mCi/ml
14C-mannitol or 100 mM Lucifer yellow was added
to monitor cell monolayer integrity. At the indicated time points,
Figure 1. Model of the Confluent Monolayer of Polarized Cells.
Model of a confluent cell monolayer, with the apical membrane on top
and the basolateral membrane below, where it binds to the
polycarbonate insert. P-gp expressed on the apical membrane
transports substrate from the inner apical membrane monolayer into
the apical chamber. The concentration of substrate in the apical and
basolateral chambers, CA and CB, are measured, while the concentration
of substrate in the inner plasma membrane, CPC, and the cytosol, CC, are
predicted as part of the mass action modeling and data fitting process.
Some compounds use other transporters expressed by the MDCKII-
hMDR1 confluent cell monolayer. Passive permeability occurs in both
directions.
doi:10.1371/journal.pone.0025086.g001
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chambers, mixed with 10 ml of Ultima Gold scintillation cocktail
and counted using a Hewlett Packard Liquid Scintillation Counter
or using the Perkin Elmer TopCount [23], [29], [30]. While the
data for amprenavir, quinidine and loperamide were obtained in a
single 4–6 hour experiment, a step-wise development of the
digoxin data was used for the Particle Swarm fitting algorithm to
determine the kinetic parameters. This has been explained in the
supporting material (Text S1 and Figures S1, S2, S3 and S4).
Fitting of data sets using particle swarm
We adapted the particle swarm program [31] to fit the
elementary rate parameters for our data sets. The program is
written in MATLAB (Natick, MA), using ODE23s numerical
integrator, since other numerical integrators deviate at the long
time points. The ‘‘goodness of fit’’ to a particular drug data set was
quantified by the coefficient of variation, ,CV/dataset., defined
as the standard deviation between the data and the simulated fit
divided by the initial drug concentration. This normalizes the
comparisons of fits over different initial drug concentrations. The
fit for a particular drug would be quantified by the average of all
CV/dataset for that drug. The fittings and most simulations were
performed on a 24-Microway processor cluster at the Department
of Scientific Computing and Mathematical Modeling, GSK,
Upper Merion, PA. Drug equilibrium partition coefficients were
obtained previously [23].
Briefly, the program starts with a user assigned number of
particles that are randomly deployed over the entire multi-
dimensional parameter space, within user assigned upper and
lower bounds, unless otherwise noted. The particles are allowed to
randomly explore the entire parameter space. Each particle
reports its coordinates and CV to the manager processor, which
determines the particle with the lowest CV and then randomly
reassigns the particles to new positions, with a small bias toward to
coordinates of the current minimum CV. This dual particle and
swarm memory is used to not only stochastically explore the
parameter space, but to converge to the global minimum. This
particular version of the many implementations of particle swarm
has the advantage that it includes an additional step of local
polling of the objective function, which allows the particle to be
moved out of a local minimum. The particle swarm approach
searches all the dimensions simultaneously, so there are no implicit
biases in the search for the global minimum. The process stops
when either all of the particles have converged to the same global
minimum or when the number of function evaluations exceeds a
pre-assigned maximum.
Results
We start by showing the outcome of one fitting, out of a total of
72, in order to explain the amount and quality of the data being
fitted and how the fitting algorithm evolved. Fig. 2 shows the fit for
100 mM amprenavir. The amprenavir concentrations used were
larger than those used for the other drugs because it has the
weakest binding constant to P-gp and the fastest efflux rate
constant from P-gp that we have measured to date [32]. So
relatively large concentrations are needed to reach saturating
levels, i.e. curvature in the transport curve within 3 hrs of
transport. This curvature shows that the system is reaching steady-
state, where the P-gp efllux out of the cells into the apical chamber
equals the passive permeability and facilitated transport into the
cell from the apical chamber.
Each data set has 4 curves to be simultaneously fitted. There is
the time course for the donor and receiver chambers for B.A
transport: B:B.A (the probe-substrate concentration in the
basolateral chamber when the basolateral chamber is the donor)
and A:B.A (the probe-substrate concentration in the apical
chamber when the basolateral chamber is the donor), i.e. the
amprenavir concentration in the donor chamber and in the
receiver chamber, respectively. There is also the time course for
the donor and receiver chambers for A.B transport: A:A.B (the
probe-substrate concentration in the apical chamber when the
apical chamber is the donor) and B:A.B (the probe-substrate
concentration remaining in the basolateral chamber when the
apical chamber is the donor), respectively. The 6 min time point
establishes a measured initial concentration in both compartments.
All data sets have 9 time points ending at 4 or 6 hours,
depending upon how long it took to achieve adequate curvature in
the data. The error bars are the standard deviation from triplicate
wells. Thus, the average of triplicates yields 36 data points within
each dataset. The solid line shows the fit using the fitted kinetic
parameters shown below in Table 1. All of the amprenavir data
have been fitted with just two drug specific numbers: the
dissociation rate constant from P-gp back to the membrane, kr,
and the efflux rate constant from P-gp into the apical chamber, k2.
The drug independent numbers for the fitted values of the P-gp
efflux active surface density, T(0), the association rate constant
from the membrane to P-gp, k1, were simultaneously fitted using
all drug datasets, as shown below.
Fitting the kinetic parameters by Particle Swarm
We had a large number of drug data sets that had to be fitted
simultaneously. For each drug, the number of data sets and drug
Figure 2. Amprenavir transport over 6 hours across the
MDCKII-hMDR1 cell monolayer. Amprenavir transport A.B and
B.A over 6 hours across the MDCKII-hMDR1 confluent cell monolayer
with 100 mM on the donor side initially. The symbols show the data
points with error bars showing the standard deviation of triplicate
measurements. A:B.A denotes the substrate concentration in the
apical chamber when the basolateral chamber is the donor, while
B:B.A denotes the substrate concentration remaining in the donor
basolateral chamber. The A:B.A transport is high because P-gp actively
pumps drug into the receiver apical chamber. The B:A.B denotes the
substrate concentration in the basolateral chamber when the apical
chamber is the donor, while A:A.B denotes the substrate concentra-
tion remaining in the donor apical chamber. The B:A.B transport is low
because P-gp actively pumps drug back into the donor apical chamber.
The lines show the best fits for amprenavir transport assuming there are
no other transporters except P-gp.
doi:10.1371/journal.pone.0025086.g002
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amprenavir with 5 datasets and concentrations varying from 50–
150 mM; quinidine with 6 datasets and concentrations varying from
1–10 mM; and loperamide with 8 datasets and concentrations
varying from 0.1–1 mM. This yields 19 datasets. For the data in
Acharya et al. [29], [30] there were: amprenavir with 14 datasets
and concentrations varying from 20–100 mM; quinidine with 10
datasets and concentrations varying from 0.1–10 mM; loperamide
with 25 datasets and concentrations varying from 0.01–30 mM; and
digoxin with 4 datasetsand concentrations varying from 10–50 mM.
This yields 53 datasets. All together there were 72 datasets, each
with 36 data points over time to be fitted, i.e. 2592 total data points.
The point is that there are far more data points to be fitted
simultaneously than the 13 parameters we eventually fit here.
For all drugs, the highest concentrations yielded nearly saturated
P-gp binding, so that P-gp mediated transport was a small
contribution to the net passive flux. The smallest concentrations
yielded fairly linear curves due to sparse P-gp binding. Overall, the
entire dynamic range of transport for each drug was covered,
allowing each of the rate constants to be measured. In other words,
there was no single step that was rate-limiting at all drug
concentrations. This is why all rate constants could be fitted and
why the Michaelis-Menten steady-state equations do not yield KM
values correlated with the elementary rate constants [27].
Fitting the drug independent values: T(0) and k1
Previously we found that the fitted total P-gp surface density,
T(0), was drug independent [23]. Since each dataset was fitted
separately in the old algorithm, a T(0) was fitted for each dataset
and we found that they clustered together. That was a benchmark
for our fitting approach, since there is only one species of P-gp. By
the old approach we also found that the association rate constant,
k1, was drug independent [23], which made sense if the entry to
the P-gp binding site is large compared to the molecular sizes of
the drugs we studied [8].
Our first step here was to determine whether the Particle
Swarm algorithm would show that T(0) and k1 could be fitted to
consensus values for all of the drug data we had. We assumed that
all drugs had a kr and k2 for P-gp, Eq. 1. Amprenavir and quinidine
required no other transporters. We verified that loperamide
required a basolateral transporter and digoxin required both a
basolateral transporter and an apical transporter, see supporting
material (Text S1 and Table S1) [29].
Preliminary separate fits of the data of Tran et al. [23] and
Acharya et al. [29], [30] showed no significant difference in the
fitted parameters. So, all the datasets were simultaneously fitted for
T(0) and k1. The drug specific kinetic parameters were fitted using
just the specific drug datasets, e.g. the digoxin specific kinetic
parameters were fitted using only the digoxin datasets.
To estimate the uncertainty of the fits for T(0) and k1, we used a
Monte Carlo approach by running 24 independent replicate
fittings. This would yield 24 independent {T(0), k1} pairs of
optimal fits, each of which had an associated vector of the other
drug-specific rate constants. If the fitting surface were a smooth
‘‘funnel’’, we would expect all replicate fits would come to roughly
the same point. This was not the outcome, but the ranges we
Table 1. Averages and standard deviations of transport parameters for the 24 independent replicate fits.
Substrate
Association
to P-gp
k1 (M
21 s
21)
a
average±sd
{range}
Efflux Active
P-gp Surface
Density
[P-gp]
(per mm
2)
b
Dissociation
from P-gp
To Apical
Bilayer
kr (s
21)
c
Efflux to
Apical
Chamber
k2 (s
21)
d
Partition
Coeff.
e
KPC
Binding Constant to
P-gp from Inner
Apical Membrane
KC (M
21)
f
=k1/kr
Passive Permeability
Coefficient at
steady-state
g
(nm/sec)
Other
Bidirectional
Transporter
h
(s
21)
PBA PAB kB kA
Amprenavir
(n=19)
(160.4)610
+8
{(0.6–2)610
+8}
8006200
{500–1300}
(260.8)610
+5
{(0.9–4)610
+5}
3068
{17–45}
200620 6006100
{400–900}
420650 350630 0 0
Digoxin
(n=4)
Same as
above
Same as above (361)610
+4
{(2–7)610
+4}
361
{1–6}
100
i 3,0006200
j
{2700–3300}
50610 40610 4063
{35–45}
40620
{20–95}
Loperamide
(n=31)
Same as
above
Same as above (462)610
+4
{(2–7)610
+4}
0.460.08
{0.2–0.5}
3,0006600 3,0006400
{2000–4000}
320690 320670 10067
{90–120}
0
Quinidine
(n=16)
Same as
above
Same as above (864)610
+
{(4–20)610
+3}
360.4
{1–4}
700630 (160.2)610
+4
{(0.9–2)610
+4}
670650 670650 0 0
ak1 is the drug independent association rate constant from the membrane to P-gp. The average value6standard deviation for the 24 independent replicate fits obtained
for all drugs is shown, while the entire range is shown in curly brackets, Fig. 3C.
bT(0) is the surface density of efflux active P-gp in the apical membrane inner monolayer for all drugs. The average value6standard deviation for the 24 independent
replicate fits obtained for all drugs is shown, while the entire range is shown in curly brackets, Fig. 3C. The units P-gp/mm
2 can be converted to mmols P-gp per liter of
inner apical membrane simply by dividing by 0.8 [23].
ckr is the dissociation rate constant from the P-gp binding site into the apical bilayer. The average value6standard deviation for the 24 independent replicate fits
obtained for all drugs is shown, while the entire range is shown in curly brackets, Fig. 4A.
dk2 is the efflux rate constant from the P-gp binding site into the apical chamber. The average value6standard deviation for the 24 independent replicate fits obtained
for all drugs is shown, while the entire range is shown in curly brackets, Fig. 4A.
eThe partition coefficient between the cytosol and the inner plasma/apical monolayer, KPC [23]. Cell membrane partition coefficients were estimated using 0.1 mm
extruded unilamellar liposomes (LUV) whose lipid compositions mimic roughly the lipid compositions of the respective membrane monolayers: inner cytosolic PS/PE/
chol (1:1:1); apical outer, PC/SPH/chol; and basolateral outer, PC/chol (2:1). Only the inner cytosolic partition coefficient, KPC, is shown in this table.
fKC=k1/kr is the substrate binding constant from inner apical membrane monolayer to P-gp. The average value6standard deviation for the 24 independent replicate fits
obtained for all drugs is shown, while the entire range is shown in curly brackets, data not shown. This value is calculated from the actual fitted values, rather than the
average 1-digit values of k1 and kr reported in the Table.
gPBA and PAB refers to the +GF120918 steady-state passive permeability coefficient, B.Aa n dA .B respectively. These values increase initially to a final steady-state value
[32], which is reported here as an average value6standard deviation over all relevant datasets.
hkB and kA refers to the 1
st order rate constant for transport through a bidirectional transporter for digoxin and for loperamide. The average value6standard deviation
for the 24 independent replicate fits obtained for all drugs is shown, while the entire range is shown in curly brackets, Fig. 4B.
iDigoxin’s partition coefficients have not yet been measured. We set it to 100, as that is the lower bound for measured values.
doi:10.1371/journal.pone.0025086.t001
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parameters and the standard deviation of the fitted parameters.
Preliminary fittings showed that the upper bound for the
concentration of efflux active P-gp, T(0), had to be set to
2.5610
23(M) within the inner apical membrane, which would be
equivalent to P-gp occupying about 25% of the efflux active apical
plasma membrane surface. This would be too high for a final
answer, but it is acceptable as an upper bound. Reducing the
upper bound led to some clustering of intermediate fits near this
upper bound, which must be avoided. The upper bound for the
association rate constant, k1, was set at 1610
9 (M
21 s
21), which
would be in the range of lipid lateral diffusion control [23]. The
lower and upper bounds used for all of the fits are shown by the
range of the x- and y-axes in the figures. Lower bounds were
always well below the fitted values.
We found that the fittings needed to be done in sequential
rounds. The first round result for {T(0), k1} is shown in Fig. 3A,
where the axes show the upper and lower bounds for the fitting.
The empty triangles show the outcome for each of the 24 replicate
fittings. All individual fits cluster near, but not at, the upper
bounds for both parameters. The average values over the 24
independent fits of the log10{T(0) (M)}=22.960.3 and log10{k1
(M
21 s
21)}=8.160.4, shown by the solid triangle, with standard
deviations shown by the error bars. The average ,CV/
dataset.=0.03, over all 72 datasets, while the old algorithm
gave about ,CV/dataset .=0.04. This is a 30% improvement in
the average fit quality and the fitted rate constants are quite
different from the old algorithm.
This fitting run terminated when the maximum number of
budgeted function evaluations was exceeded, which means that the
Figure 3. Simultaneous fits of P-gp efflux active surface density, T(0), and association rate constant, k1. 24 independent replicate fits of
all 72 experimental data from Tran et al. [23] and Acharya et al. [29], [30]. All 13 kinetic parameters were simultaneously fitted to all relevant datasets.
For all figures, the x- and y-axes show the user-fixed lower and upper bounds used in each fitting round. Fig. 3A shows the 1
st round of fitting for the
drug independent values of the surface density of efflux active P-gp in the apical membrane, T(0), and the association rate constant k1. The open
triangles show the 24 individual fitted values. The solid triangle shows the log-average and the error bars are the standard deviation for the 24
individual fits, which are also written onto the figure. The average coefficient of variation over all data sets and the 24 replicate fits, ,CV/dataset.,i s
also shown with its standard deviation. Fig. 3B shows the A:B.A trajectories of 6 randomly chosen fits from the data for 30 mM digoxin transport, as
an example. Four of the trajectories are on-target with the data, one is close and one is off-target. Fig. 3C shows the results for the 2
st round of 24
independent replicate fits, which was started as a fresh run with upper and lower bounds shown by the dashed box in Fig. 3A, together with
appropriately reduced upper and lower bounds for the drug dependent kinetic parameters. The consensus average values, standard deviations and
the ranges are given in Table 1. Fig. 3D shows the A:B.A trajectories of 6 randomly chosen fits from the 2
nd round for 30 mM digoxin transport, like
Fig. 3B. All six trajectories are on-target with the data and tighter than found in Fig. 3B for the 1
st round, hence the reduced range of fitted values.
doi:10.1371/journal.pone.0025086.g003
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converging to the same place. In order to visualize the end point of
this fitting run, Fig. 3B shows 6 randomly chosen curves for the fits
to the 30 mM digoxin data as an example. Four of the curves are
clustered close to the data, while one diverges higher after about
12 hrs and one curve is significantly lower than the data. All 24
curves could be displayed, but the result is cluttered and yields the
same basic conclusion, i.e. roughly a third of the fits were off target
at this stage.
The CV for all 24 replicate fits was between 0.0259–0.0262, i.e.
nearly identical. Fitting on a surface where the CV is nearly
constant is inefficient. So rather than increasing the budget of the
maximum number of function evaluations, we adjusted the upper
and lower bounds to those shown by the dashed boxed area in
Fig. 3A. In addition, we adjusted the upper and lower bounds for
all the drug dependent kinetic parameters in the same way, i.e.
including all fitted values and adding a small buffer zone, about
10–20%. This substantially reduced the volume of the parameter
space to be explored in the 2
nd round, which started with a
random dispersal of particles within the upper and lower bounds.
The 2
nd round of fits ended with the maximum number of
function evaluation being exceeded, like the 1
st round. The result
is shown in Fig. 3C. The average values of log10{T(0)
(M)}=23.060.1, log10{k1 (M
21 s
21)}=8.060.15 and the
,CV/dataset.=0.026, i.e. there was little change in the average
values from the 1
st round. However, their standard deviations
decreased about 3-fold in all measures from the 1
st round. In order
to visualize this stage of the process, Fig. 3D shows 6 randomly
chosen curves, which were not related to the 6 curves shown in
Fig. 3B, since all fitting rounds were completely restarted. All 6
curves are clustered close to the data and show the convergence of
the replicates to the same best-fit curve. None of the replicate fit
values clustered near the new upper or lower bounds.
The upper and lower bounds were adjusted for a 3
rd fitting
round, as was done for the 2
nd round. At the end of the 3
rd round,
the average values of the fitted T(0) and k1 did not change up to 3
significant digits. However, the average ,CV/dataset. of the
replicate fits increased slightly from the 2
nd round, suggesting that
some of the upper and lower bounds for the other kinetic
parameters were too restricted, despite being set outside the
endpoints of the 2
nd round. Since the estimated values of T(0) and
k1 were essentially identical to those of the 2
nd round and well
within experimental error of the individual experiments, we
discarded the 3
rd round and continued the analysis of the fitted
values from the 2
nd round. The primary function of the 2
nd round
was to tighten the range for the drug dependent kinetic parameters
to within around a factor of 3 or less, which allowed the simplest
calculation of averages and standard deviations of the parameters
themselves, not their log10 values.
Consensus fits and ranges of the fits from the 2
nd Round
Table 1 contains the consensus fits for the kinetic parameters.
The first column is the consensus for the association rate constant
to P-gp from the membrane k1=(160.4)610
8 (M
21 s
21), to 1
significant digit. The whole range for k1 in Fig. 3C for the 24
replicate fits was {0.6–2}610
8 (M
21 s
21) is shown underneath in
curly brackets, {}, again to 1 significant digit. These numbers are
drug independent.
The efflux active P-gp surface density is the next consensus fit
shown in Table 1, in the units of P-gp/mm
2. The average and
standard deviation for the 24 replicate fits was 8006200 P-gp/
mm
2, while the range was {500–1300}, shown underneath in
curly brackets.
The fits for the drug dependent values for P-gp from the
2
nd round: kr, k2 and KC
We next looked at the fits for the drug dependent kinetic
parameters. Fig. 4A shows the drug specific parameters {kr, k2}
accompanying the 24 replicate values for {T(0), k1} shown in
Fig. 3C. The open symbols show the individual fitted values. The
closed symbols show the consensus average values of kr and k2 for
each drug, error bars show the standard deviations. Table 1 shows
the average and standard deviations calculation from the direct
values, not their log10 values. The ranges from the 24 independent
replicate fits are shown underneath the consensus average values
in Table 1 in curly brackets.
Figure 4. 24 independent replicate fits from the 2
nd fitting
round for drug dependent kinetic parameters. Fig. 4A shows the
fitted values for kr and k2 for each drug. The x- and y-axes show the
upper and lower bounds for these fits. Like Fig. 3, the open symbols
show the 24 individual fits for amprenavir (AMP, triangles), quinidine
(QND, circles) and loperamide (LPM, squares) and digoxin (DGX, x). The
closed symbols show the log-average with error bars showing standard
deviations. Fig. 4B shows the fitted values for the loperamide
basolateral transporter, kB, (LPM, squares) and for the digoxin
basolateral and apical transporters, kB and kA, (DGX, x symbols). The
closed symbols show the log-average with error bars showing standard
deviations. The x- and y-axes show the upper and lower bounds for
these parameters. The consensus average values, standard deviations
and the ranges are given in Table 1.
doi:10.1371/journal.pone.0025086.g004
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for each drug to P-gp from the membrane, with standard deviation
and the range obtained directly from the 24 independent replicate
fits from Fig. 4A, i.e. not from the average k1 divided by the
average kr. The partition coefficients for the drugs was measured
previously, using 0.1 mm diameter unilamellar liposomes whose
compositions mimic, in a simple way, the lipids of the inner plasma
membrane, KPC, the outer apical monolayer, KAO, and of the
basolateral outer monolayer, KBO [23].
Another way we fit for the drug dependent kinetic parameters
was to fix the values of T(0) and k1 at their consensus values from
Table 1 and fit all the drug dependent kinetic parameters using 12
independent replicate fits. We obtained replicate fitted values for
{kr, k2}, all of which were essentially identical to the average values
shown in Table 1, not shown. This showed that the average {T(0),
k1} value in Fig. 4A generated the average vector of drug
dependent kinetic parameters.
The fits for the other transporters
The final consensus values we need are those for the other
basolateral and apical transporters. Fig. 4B shows the 24
independent replicate fits for the basolateral transporter required
by loperamide transport kinetics (symbol squares) shown in the
units of s
21 for a first order transporter [28], [29], [30]. These
values are plotted on the kA=0 line, since loperamide did not
require an apical transporter, either here or previously [29]. The
consensus average is ,kB.<10067s
21, to 1 significant digit,
shown by the solid square with standard deviation, while the range
was (90–125 s
21). This is shown in Table 1.
The steady-state values for the +GF120918 passive permeability
coefficients of the other drugs are shown in the same column of
Table 1. GF120918 completely inhibits both P-gp and the other
transporters for loperamide and digoxin [23,28], [29], [30]. If
there are still other transporters in these cells which are not
inhibited by GF120918, then the calculated +GF120918 passive
permeability would include their contribution, in addition to the
lipid bilayer permeability coefficient.
Fig. 4B also shows the 24 independent replicate fits for digoxin’s
basolateral and apical transporters, shown in the units of s
21 for
the first order transporter (symbol x). The fits for the basolateral
transporter are fairly tight. The consensus average is about
,kB.=4063s
21, with a range of {35–45 s
21}. This tightness of
this fit was anticipated by the fit shown in Figure S4, where the
basolateral transporter was essential to get a very good fit for the
first 10 hrs of digoxin transport. The drift after 10 hrs that led to
the addition of the apical transporter was not large and the wide
range of 24 replicate fits for the apical transporter reflects this. The
consensus average is about ,kA.=40620 s
21, with a range of
{20–95 s
21}. These values have been shown in Table 1, together
with the relatively small +GF120918 steady-state passive perme-
ability of digoxin.
The other transporters for loperamide and digoxin are
better fitted by a bidirectional mechanism compared
with an active importer mechanism
We now address the question of whether the other transporters
are more likely to be bidirectional or active transporters based
upon best fitting of the data, since their identity is as yet unknown
[29]. If these transporters are active, then they must be importers,
since the problem shown in Fig. S4 is that without the basolateral
transporter, not enough digoxin is getting into the cells from the
basolateral chamber for P-gp to efflux into the apical chamber.
Then, after 10 hrs, without the apical transporter, not enough of
the digoxin effluxed by P-gp into the apical chamber was allowed
to return into the cells. Basolateral or apical exporters cannot fix
either of these problems.
Fig. 5A shows the fit for 30 mM digoxin assuming that the
basolateral and apical transporters are bidirectional, i.e. facilitate
transporter. Using the previous algorithm [30], we could not
obtain a fit for this particular data set, which is obviously fit well by
the new Particle Swarm based algorithm. Next, we changed the
basolateral and apical transporters to be importers only by setting
the rate constants for transport out of the cells to zero. This
automatically made the transporters active importers, without
complicating the kinetic model unnecessarily with ATP hydrolysis
kinetics. Of course, this did not affect P-gp. With {T(0), k1} fixed
at their consensus values in Table 1, the digoxin data was refit,
including the kr and k2 for P-gp. Fig. 5B shows the best fit for the
importers with 30 mM digoxin. For all the digoxin data, the fits
with importers are not as good as the fits with bidirectional
transporters. The difference is not huge, so neither possibility can
be completely rejected.
Figure 5. Fits of digoxin data with bidirectional or active
importers. Fits of all the digoxin data with the assumption that the
basolateral and apical transporters are bidirectional, Fig. 5A, or are
active importers, Fig. 5B. The best fits for each mechanism are shown
just for the 30 mM digoxin example, which is representative.
doi:10.1371/journal.pone.0025086.g005
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importerand foundthat the best fit,CV/dataset.=0.023over 25
datasets, as compared with ,CV/dataset.=0.020 for the
bidirectional transporters. So, the bidirectional transporters yielded
a better fit, as was the case for digoxin. However, if we refitted the
loperamide allowing both basolateral and apical importers, then the
fits were about the same as with just the basolateral bidirectional
transporter. So, the loperamidetransporters could be importers, but
then but we would also require an apical importer for loperamide.
We did not try other permutations.
Fitting model data without error
We wanted to know whether the ranges of the {T(0), k1} fits in
Fig. 3 were due to experimental error. Using the consensus values
obtained from the fits of experimental data, Table 1, we simulated
model data without error for all the four drugs with concentra-
tions: 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 mM, while including 100 and
200 mM for amprenavir to reach P-gp saturation. If experimental
error were the cause for the range in T(0) and k1 fits, then the
simulated data without error should yield a smooth funnel-like
fitting surface with a common minimum at the parameter values
used to simulate the data in the first place. The same fitting
protocol used with the experimental data was followed.
For the model data without error, the 1
st and 2
nd rounds of fits for
{T(0), k1} with 24 independent replicate fittings, showed a similar
broad range of fits just like the experimental data fittings in Figs. 3A
and 3C, data not shown. The averages of the 24 replicate fits for the
model data were essentially identical to the values used to simulate
the data in the first place, data not shown. The ,CV/dataset. of
the model data fits were smaller by a factor of over 100-fold, as
expected. So the range in the fits of the experimental data is not due
to experimental error. The reason will be discussed below.
Discussion
Using the transport data across a confluent monolayer of
MDCKII-hMDR1 cells, we have constructed a molecular model
of the P-gp membrane transport network based upon fitting the
elementary rate constants of P-gp, the rate constants of other
required transporters, as well as the passive permeability coefficients
and partition coefficients [23], [29], [30]. All these components will
be required to simulate the P-gp transport network for these and
other drugs. Other cell lines or in vivo systems may well have other
transporters, but our new kinetic analysis can identify their
functional requirements for the observed substrate transport.
The ability to have simultaneous and relatively rapid fits over all
relevant data sets overcomes the limitations of our previous
method, while simplifying and clarifying the fitting process. For
example, we can now survey data to find which drugs require
other transporters and in which membrane, Table S1. If another
transporter is required, we can survey the fitness of the potential
mechanisms of that transporter, e.g. bidirectional/facilitated or
active/importer or exporter, by determining which mechanism
yields the best fit.
We will first discuss the sensitivity of the kinetic parameter fits,
then we will discuss how the range of the fitted parameters is due
primarily to compensation between kinetic parameters within this
P-gp transporter network rather than experimental error and finally
we will discuss howthe valuesof the kinetic parametersexplicate the
biological function of P-gp and the other transporters.
Sensitivity of the fits for the kinetic parameters
The fitted parameters from any multivariate nonlinear model
are always subject to the question of parameter sensitivity, i.e. how
much difference in the fit occurs with deviations from the ‘‘best’’ fit
kinetic parameters. To answer this question we used independent
replicate fits, i.e. a Monte Carlo approach. The maximum number
of function evaluations was set at 12,000, which yielded a
reasonable compromise between duration of a serial run, roughly
a month, and compactness of endpoint parameter ranges.
At the end of the 1
st fitting round, Fig. 3A, which exhausted our
budget for function evaluations, we determined new upper and
lower bounds for all the parameters that encompassed their 24
endpoint values, with about a 10% buffer zone above and below
for each fitted parameter. We could have restarted the fits from the
endpoints of the 1
st round or simply started a new run from within
the new boundaries. It was both simpler and more in keeping with
the Particle Swarm philosophy to start fresh. This resulted in the
endpoint of the 2
nd fitting round in about 2–3 weeks, Fig. 3C for
T(0) and k1.
The average values of the efflux average surface density of P-gp,
T(0), and the association rate constant, k1 did not change
significantly between the 1
st to 2
nd rounds, Figs. 3A and 3C.
The average fit got slightly better, ,CV/dataset.. What really
changed was the standard deviation of the average parameters,
which is visualized by the difference between the six randomly
chosen fits for the 30 mM digoxin A:B.A data after each of the
two rounds, Figs. 3B and 3D. At the end of the 1
st round, 4 of the 6
fits are close to target, 1 is ok and 1 is off target. At the end of the
2
nd round all 6 of the fits are on target and nearly identical. Thus
the 2
nd round allowed the ‘‘laggard’’ fits to hit the data and tighten
up a little, which accounts for a 3-fold decrease in the standard
deviations for the fitted kinetic parameters.
Each of the final fits for {T(0), k1} fits, Fig. 3C, had an
associated vector of the drug dependent kinetic parameters, fitted
simultaneously using just the drug specific datasets, including the
other transporters for loperamide and digoxin. With the 2
nd round
of fitting, all the kinetic parameters were within a 3-fold range,
allowing us to simply average all these independent replicate fits,
using their Cartesian (not logarithmic) values, and take their
standard deviations, as shown in Table 1. The sensitivity of all
these fitted parameters is very good, e.g. the standard deviations
are ,50% of the averages, Table 1. Given the complexity of the
confluent cell monolayer and the rigor of our fitting, the error bars
on the fitted parameters shows that the data is very tight.
Our next question about the fitting process was whether the
{T(0), k1} range was due to the experimental error in the data. To
answer this question, model data without error was simulated
using the consensus values of the kinetic parameters shown in
Table 1. We fitted this simulated data following the same protocol
as was used with the experimental data, including using 24
independent replicate fits. We found that the range of fitted values
from these model data at the 1
st and 2
nd rounds was essentially the
same as those for the experimental data shown in Fig. 3, i.e. no
more compact. The average fitted values were essentially identical
to the consensus values used to simulate the model data in the first
place. So, the range of the fitted parameters is not due to
experimental error.
Fitted Parameter Compensation
The range of kinetic parameter fitted values is due primarily to
compensation between kinetic parameters, yielding essentially the
same transport trajectory, e.g. Fig. 3D. This compensation can
occur only over a limited range of parameter values, since
otherwise one of the parameters would be redundant. This means
that there is no single rate-limiting step for transport at all
substrate concentrations for any drug. One rate constant will
dominate at low substrate concentrations, while other rate
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tions, until transporter saturation was achieved. This is why the
steady-state Michaelis-Menten equations, which assume a single
rate-limiting step over the substrate concentration range, cannot
give reliable estimates of Vmax and KM in terms of the elementary
rate constants [27].
As rate determining dominance passes from one step in the
transport process to another, there is a small zone of compensa-
tion. We illustrate this with a few examples. Table 1 shows that the
value of T(0) ranges from 500–1300 P-gp per mm
2, while the CV
for all runs was essentially the same. So which kinetic parameters
compensate to achieve essentially the same amount of transport
within this zone?
This is shown using amprenavir, whose transport depends only
on P-gp. The two fits showing the extreme values of T(0) out of the
24 runs, i.e. 500 and 1300 P-gp/mm
2, have kr values of (1.4 and
1.9)610
5 s
21 and k2 values of (45 and 17) s
21, respectively. kr is not
much different, but the value of k2 changes substantially. In fact, at
the T(0) extremes, the product of k2T(0) has the values of {(2.25
and 2.21)610
4 P-gp/(mm
2 s)}, i.e. they are essentially identical.
Previously, we found that that the product of k2T(0) was an
important determinant for the fits [23]. Small variations in the
fitted P-gp surface density can be compensated by inverse
variations in the fitted efflux rate constant k2, such that their
product remains essentially constant for a particular drug.
Likewise, small variations in k1 could be compensated by direct
variations in kr, so that their ratio, KC=k1/kr, would remain
essentially constant [23]. These two types of compensation is
strong for drugs like amprenavir and quinidine which have only kr
and k2 to provide compensation for variations in T(0) and k1.
Loperamide and digoxin have the other transporters which can
be involved in kinetic compensation. The range for loperamide’s
kB for its basolateral transporter was 90–124 s
21. For the fits
showing the two extreme values, the values for kr are (2.3 and
7.2)610
4 s
21 and for k2 are (0.31 and 0.39) s
21, respectively.
Clearly, an increase in the value of kB, which would allow more
drug into the cell to bind to P-gp, was compensated mostly by the
increase in kr, the drug dissociation rate from P-gp back into the
membrane, which would decrease the drug binding constant to P-
gp. This yields about the same amount of drug bound P-gp and
efflux of drug into the apical chamber. The same compensation
pair is found with digoxin.
Compensation can involve more than just pairs of kinetic
parameters. Fig. 4B shows that the apical digoxin transporter
shows a large range in the fitted kA rate constant, from 95 to
22 s
21. At these two extremes, the kr values are (5.35 and
5.42)610
4 s
21, while k2 values are (4.2 and 1.6) s
21. Before simply
assigning the compensation to k2, since kr does not change much,
we must first check whether T(0), another compensatory partner
of k2, is different For the extreme values of kA, T(0) has values of
(1300 and 1100) Pgp/mm
2, so the product of k2T(0) has the values
of (5.5 and 1.8)610
3 P-gp/(s-mm
2). The compensation is due
mostly to these three kinetic parameters: kA versus the product of
k2T(0).
Compensation explains why model data without error does not
have a funnel-like fitting surface. This points out why we cannot
expect funnel-like fitting surfaces for multivariable transport
networks, or probably any complex biochemical network.
The values of the kinetic parameters
We have shown that fitted parameters are valid and their ranges
make sense, so we can turn to what their numerical values imply.
The values in Table 1 are different than those published previously
using to the older algorithm. The difference is due to the fact that
the Particle Swarm algorithm could fit all of our data
simultaneously.
We start with the association rate constant k1. Since P-gp has its
binding site in the inner apical monolayer [3], [5], [8] and all
known P-gp substrates are amphipathic, it makes sense that the
kinetically favored pathway to P-gp would follow the inner plasma
membrane at the lipid lateral diffusion rate until it binds to P-gp.
Our fitted k1 is at the lipid lateral diffusion control range [23]. This
would be a very rapid pathway, with the drug being able to diffuse
through about half of inner monolayer of the plasma membrane,
,20 mm in diameter, in 1–2 minutes. While P-gp probably
evolved from a transporter of endogenous substrates, its current
job in humans and other species appears to be the efflux of
xenobiotic molecules, which come in all sizes and polar/nonpolar
shapes [20], [33]. Thus, it also makes sense that P-gp’s portal of
entry to its binding site is large [8], which is also required for a
large k1.
What about the efflux active P-gp surface density, T(0)? The
term efflux active simply acknowledges our finding that the height
and separation of the microvilli will determine which P-gp’s can
efflux drugs that can reach the apical chamber, where they are
collected and assayed [23], [29]. Basically, in a random walk after
efflux, only drug effluxed near the tips of the microvilli can be
expected to reach the apical chamber in a timely fashion. The rest
are adsorbed back into the microvilli membrane and recycled.
The efflux active P-gp surface density was fitted as 8006200 per
mm
2 or about 2610
22 mg P-gp/cm
2, assuming a molecular
weight of 170 kD [34]. Rosenberg et al. [34] reported electron
microscopy of P-gp proteosomes showing an average 10 nm
diameter, including lipids. This means that P-gp will occupy
roughly 100 nm
2 of the apical membrane surface, i.e. close
packing would yield roughly 10
4 P-gp/mm
2 or about 0.3 mg P-
gp/cm
2. Thus, our fitted value for the P-gp surface density
occupies only about 8% of the available apical membrane surface
area, which seems reasonable for an overexpressed membrane
protein. None of the fitted values in the 2
nd round came close to
the upper bounds for P-gp, Fig. 3C. A recently reported value of
over 300 mg P-gp/cm
2 for the hMDR1-MDCKII cells [35]
cannot be correct, as it is about 1000-fold higher than close
packing.
The selective pressure on P-gp appears to be maintenance of
very broad substrate specificity, thus its binding constant to all
xenobiotics should be relatively weak. Table 1 shows that 1/KC is
in the mM range, with respect to dissociation back into the apical
membrane. Thus, the binding to P-gp from the membrane is
weak. However, the binding constant to P-gp relative to the cytosol
is the inverse of the product of the substrate’s partition coefficient
and its binding constant, i.e. KD=1/(KPC.KC). Our measured
partition coefficients to liposome mimetics of the cell membrane
monolayers (23) are greater than 100. These two parameters allow
P-gp to bind and efflux substrates with micromolar cytosol
concentrations.
Since the association rate, k1, is large and the binding constant
KC is small, the dissociation rate constant back into the apical
membrane, kr=k1/KC, must be large, as the fit shows in Table 1.
The ratio of kr/k2 estimates the number of bound substrate
molecules that return to the apical membrane for each one
effluxed into the apical compartment. From Table 1, this number
ranges from about 3,000 for quinidine to 100,000 for loperamide.
Thus, only the rare substrate occupying the P-pg binding site is
actually effluxed, compared with the number dissociating back
into the lipid bilayer.
This might appear inefficient usage of ATP, but P-gp’s ATPase
activity has not been measured to be higher than the maximal rate
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21 [36], which we took for the upper bound for k2
in our fitting. Protein ATPase activity may not be able to get much
larger. However, this ‘‘inefficiency’’ vanishes when we consider
that P-gp’s job is to keep xenobiotics out of the cytosol, not out of
the plasma membrane of the cell. This means that the efflux rate
constant of P-gp is not competing against the return of drug to the
membrane, but rather against permeation of the drug into the
cytosol from the inner monolayer of the plasma membrane.
Previously, we estimated that the rate of passive permeation of
these substrates from the membrane into the cell cytosol were
roughly 10 times slower than the smallest efflux rate constant [30],
[37]. We can make more accurate estimates with our new values
for the kinetic parameters. The equation needed is,
PAC:Ac=VC ðÞ
k2
%
1
k2
2|PAB(nm=s) 2|1:13cm2 
1mL

~4:5|10{4(nm{1)
PAB(nm=s)
k2 s{1 ðÞ
ð2Þ
where PAC.AC/VC is the passive permeability coefficient from inside
the apical membrane to the cytosol times the area of the apical
membrane divided by the volume of the cytosol. This is the first
order rate constant, units of s
21, for the permeation from apical
membrane interior to cytosol.
For simplicity, we use the entire apical membrane and cytosol of
the confluent cell monolayer, rather than each individual cell. PAC
is roughly equal to twice the A.B passive permeability, since
passive permeability across membranes in series is like resistance,
i.e. PAB<1/(1/PAC+1/PBC) [12], [23], which accounts for the two
barriers. Assuming they are equal gives PAC=2 6PAB. For the area
of the apical membrane, we have used twice the plastic insert area,
261.13 cm
2, simply to get the same passive permeability
coefficient for the cell measurements, with two membranes, and
the standard measurement using the 1-barrier equation [23]. Since
the fit for k2 also assumes efflux active P-gp surface area, the effect
of the microvilli size and shape are roughly normalized out of this
ratio.
For amprenavir, digoxin and quinidine, the Eq. (2) ratio is
roughly 0.006, 0.004 and 0.08, respectively. Thus, P-gp keeps
these drugs out of the cytosol with well over a 10-fold difference.
For loperamide, the ratio is about 0.4–0.5, due to its much smaller
fitted efflux rate constant. This suggests that loperamide is not as
well cleared by P-gp from the cytosol as the other drugs. Further
study with loperamide is warranted to understand why this is
adequate for cell viability in different cell lines and tissues.
The range of values of the efflux rate constants, k2, covers nearly
2 orders of magnitude, i.e. from 0.4 s
21 for loperamide to 30 s
21
for amprenavir. Rank ordering of P-gp binding constants, KC,o r
equivalently the dissociation rate constants, kr, for the substrates is
not monotonic with the rank ordering of efflux rate constants,
showing that the molecular properties dominating these two
reaction steps are not identical.
It is known that ATP hydrolysis by P-gp is required to efflux
drugs [5], [9], [13], [20], [34]. The stoichiometry of ATPase
activity to transport has been studied [5], but there is no definitive
answer. The efflux rate constants we measure here will provide the
best correlation between ATPase activity and efflux stoichiometry.
The ATPase activity of P-gp depends on many factors and adding
lipid to the purified protein increases the activity [37], [38], [39],
[40], [41]. Many different values are reported, even for the same
drugs.
It has been reported that the ATPase activity of purified P-gp
reconstituted into proteosomes in 10 mM quinidine was about
4–6 mmol ATP hydrolyzed/min/mg P-gp [40]. This protocol
gives consistent measurements for ATPase rates for other drugs
[8], [22], [38]. This translates roughly to 10–15 s
21 ATPase
activity compared with our fitted efflux rate constants of
k2=3s
21, for both drugs. This suggests that the stoichiometry is
about 3–5 ATPs hydrolyzed per quinidine molecule effluxed. This
is significantly different from the commonly cited 1:1 stoichiometry
[5]. Obviously, many more cases will have to be examined before
a conclusion can be reached. It may well be that the stoichiometry
is not the same for all P-gp substrates.
The final kinetic parameters we need to discuss are the rate
constants of the other transporters. For the loperamide basolateral
transporter, the first order rate constant for the bidirectional
mechanism was kB=100 s
21 and no apical transporter was
required. When the loperamide data was fitted using just the
basolateral importer, the fit was worse. However, when we allowed
both basolateral and apical importers for loperamide, the fits were
basically the same as for just the bidirectional basolateral
transporter. The fitted values for the importer mechanism were
kA,IMP=50s
21 and kB,IMP=100 s
21. Interestingly, the rate
constant for the basolateral transporter did not depend on whether
it was bidirectional or an active importer. This makes sense in that
loperamide influx from the basolateral chamber was crucial to
achieving good fits the data, which would be essentially the same
whether the transporter was bidirectional or an active importer.
The apical importer value of kA,IMP=50s
21 was compensated by
a decrease in kr, to increase P-gp binding of loperamide and
increase efflux to the apical chamber. k2 did not change much.
Thus, for loperamide, there are two reasonably clear alternatives
for the other transporters.
When the other digoxin transporters were modeled as
bidirectional/facilitated, there is the intriguing finding that both
transporters having roughly the same rate constant, raising the
possibility that it is the same transporter on both apical and
basolateral plasma membranes. This may be unusual, but not
impossible. When the digoxin transporters were modeled as
importers only, the fit was not as good as for the bidirectional fits,
Fig. 5. We do not yet have enough data for competition between
digoxin and loperamide to deduce whether they compete for the
same other transporters.
Concluding Remarks
With this new fitting algorithm, we are now in a position to
compare the kinetics of P-gp transport over a much wider range of
substrates. This will include the kinetic identification of other
transporters that affect the transport of any P-gp substrates, which
will expand the P-gp transporter network. Our fitted rate constants
make physical and evolutionary sense. The range of fitted values
we show in Table 1 is due to the compensation partnerships
between the kinetic parameters that define the P-gp transport
network, rather than experimental error. This implies that
transporter networks will not have a funnel-like fitting surface,
but rather a relatively ‘‘flat’’ global minimum neighborhood, with
respect to the coefficient of variation between the data and the
best-fit curves. This rigorous analysis of P-gp function will enhance
our understanding of how structure accomplishes this transport
function.
Future work must address how the multiple substrate binding
sites within P-gp [8] contribute to transport, whether these binding
sites are competitive or uncompetitive, and/or cooperative, either
positive or negative [11], [29], [42]. To fit cooperativity would
double the number of elementary rate constants to be fitted. The
new Particle Swarm based algorithm will facilitate rigorous surveys
of all these mechanistic possibilities.
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Figure S1 Shows just the B.A transport, for clarity,
during the first 6 hrs of transport. The transport is much
slower than that shown for amprenavir, due to digoxin’s small
+GF120918 passive permeability. The dashed lines are simply
straight lines, not fits, showing that the transport data is linear. Fits
for rate constants require curvature, such as seen with amprenavir
after 2–3 hrs.
(TIF)
Figure S2 Shows the transport over 18 hrs constructed
from three separate experiments, wherein the concen-
tration endpoints of Expt. 1, 0–6 hrs, were used for the
initial concentrations for Expt. 2, 6–12 hrs. Likewise, the
concentration endpoints of Expt. 2, 6–12 hrs, were used for the
initial concentrations for Expt. 3, 12–18 hrs. The three data sets
were stitched together to create a continuous 18 hr transport curve
which showed enough curvature to fit the kinetic parameters.
(TIF)
Figure S3 Shows the culled dataset, reduced to 9
separate time points to accommodate the fitting pro-
gram, wherein the initial time points with the straight
data, Fig. S1, and then every other time point out to
18 hrs were omitted.
(TIF)
Figure S4 Shows the fitting for the other transporters.
While all datasets were fitted, only the fits for A:B.A data are
shown. The dotted black line shows the ‘‘best’’ fit using just P-gp.
The fit requires maximal P-gp transport rate constants and is 50%
too small. Adding a bidirectional apical transporter, AT shown by
the dashed black line, makes no significant difference, since
basolateral chamber is the donor here. Adding a bidirectional
basolateral transporter, BT shown by the solid black line, allows a
very good fit to the data up to about 8 hrs, after which time the fit
overestimates the digoxin concentration in the receiver apical
chamber. Adding bidirectional basolateral and apical transporters,
BT & AT shown by the solid red line, allows a very good fit to the
data over the entire time course, since the apical transporter allows
digoxin to reenter the cytosol after P-gp efflux.
(TIF)
Table S1 Effect of adding bidirectional transporters on
fits.
(DOC)
Text S1
(DOC)
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